Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study.

Szczegóły
Abstrakt

Tytuł:: Clinical and Radiologic Response of Central Giant Cell Granuloma to Denosumab: A 6-Year Prospective Observational Study.
Autorzy:: Rhou YJJ; Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW, Australia. .
Wang CJ; Department of Oral and Maxillofacial Surgery, Westmead Hospital, Sydney, NSW, Australia.; Dental and Maxillofacial Department, Prince of Wales Hospital, Sydney, NSW, Australia.; Department of Dental and Oral Surgery, Sydney Children's Hospital, Randwick, Sydney, NSW, Australia.
Nguyen M; Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW, Australia.
Vanderniet JA; Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Munns CF; Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Coleman H; Department of Anatomical Pathology, Douglass Hanly Moir, Sydney, NSW, Australia.
Kim J; Department of Oral and Maxillofacial Surgery, Westmead Hospital, Sydney, NSW, Australia.
Holmes-Walker DJ; Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Lim L; Department of Oral and Maxillofacial Surgery, Westmead Hospital, Sydney, NSW, Australia.
Girgis CM; Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW, Australia. .; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. .; Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW, Australia. .
Źródło:: Calcified tissue international [Calcif Tissue Int] 2022 Apr; Vol. 110 (4), pp. 464-474. Date of Electronic Publication: 2022 Jan 28.
Typ publikacji:: Journal Article; Observational Study
Język:: English
Imprint Name(s):: Publication: New York Ny : Springer Verlag
Original Publication: Berlin, New York, Springer International.
MeSH Terms:: Bone Density Conservation Agents*/therapeutic use
Bone Neoplasms*/drug therapy
Giant Cell Tumor of Bone*/drug therapy
Giant Cell Tumor of Bone*/pathology
Granuloma, Giant Cell*/drug therapy
Osteonecrosis*
Adolescent ; Adult ; Denosumab/therapeutic use ; Humans ; Young Adult
References:: Jaffe HL (1953) Giant-cell reparative granuloma, traumatic bone cysts, and fibrous (fibro-oseous) dysplasia of the jawbones. Oral Surg Oral Med Oral Pathol 6(1):159–175. https://doi.org/10.1016/0030-4220(53)90151-0. (PMID: 10.1016/0030-4220(53)90151-013026160)
de Lange J, van den Akker HP, van den Berg H (2007) Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104(5):603–615. https://doi.org/10.1016/j.tripleo.2007.04.003. (PMID: 10.1016/j.tripleo.2007.04.00317703964)
Chuong R, Kaban LB, Kozakewich H, Perez-Atayde A (1986) Central giant cell lesions of the jaws: a clinicopathologic study. J Oral Maxillofac Surg 44(9):708–713. https://doi.org/10.1016/0278-2391(86)90040-6. (PMID: 10.1016/0278-2391(86)90040-63462363)
Whitaker SB, Waldron CA (1993) Central giant cell lesions of the jaws. A clinical, radiologic, and histopathologic study. Oral Surg Oral Med Oral Pathol 5(2):199–208. https://doi.org/10.1016/0030-4220(93)90094-k. (PMID: 10.1016/0030-4220(93)90094-k)
Chrcanovic BR, Gomes CC, Gomez RS (2018) Central giant cell lesion of the jaws: an updated analysis of 2770 cases reported in the literature. J Oral Pathol Med 47(8):731–739. https://doi.org/10.1111/jop.12730. (PMID: 10.1111/jop.1273029751369)
Chrcanovic BR, Gomes CC, Dos Santos TR, Abreu MHNG, Gomez RS (2019) Clinical factors associated with the recurrence of central giant cell lesions. J Oral Pathol Med 48(9):799–802. https://doi.org/10.1111/jop.12937. (PMID: 10.1111/jop.1293731353534)
Lee JC, Huang HY (2020) Soft tissue special issue: giant cell-rich lesions of the head and neck region. Head Neck Pathol 14(1):97–108. https://doi.org/10.1007/s12105-019-01086-2. (PMID: 10.1007/s12105-019-01086-2319504667021864)
Palmerini E, Picci P, Reichardt P, Downey G (2019) Malignancy in giant cell tumor of bone: a review of the literature. Technol Cancer Res Treat 18:1533033819840000. https://doi.org/10.1177/1533033819840000. (PMID: 10.1177/1533033819840000)
Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M et al (2010) Denosumab in patients with giant cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11(3):275–280. https://doi.org/10.1016/S1470-2045(10)70010-3. (PMID: 10.1016/S1470-2045(10)70010-3)
Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ et al (2019) Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 20(12):1719–1729. https://doi.org/10.1016/S1470-2045(19)30663-1. (PMID: 10.1016/S1470-2045(19)30663-131704134)
Lipplaa A, Dijkstra S, Gelderblom H (2019) Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone. Curr Opin Oncol 31(4):329–335. https://doi.org/10.1097/CCO.0000000000000529. (PMID: 10.1097/CCO.000000000000052966137246613724)
Gupta B, Stanton N, Coleman H, White C, Singh J (2015) A novel approach to the management of a central giant cell granuloma with denosumab: a case report and review of current treatments. J Craniomaxillofac Surg 43(7):1127–1132. https://doi.org/10.1016/j.jcms.2015.04.011. (PMID: 10.1016/j.jcms.2015.04.01126032758)
Hameed M, O’Connell JE, Rogers SN (2019) Management of an aggressive giant cell granuloma of the mandible with denosumab: a case report. Br J Oral Maxillofac Surg 57(7):691–693. https://doi.org/10.1016/j.bjoms.2019.05.023. (PMID: 10.1016/j.bjoms.2019.05.02331230854)
Kim TS, Usera GL, Ruggiero SL, Weinerman SA (2017) Improvement of giant cell lesions of the jaw treated with high and low doses of denosumab: a case series. JMBR Plus. 1(2):101–106. https://doi.org/10.1002/jbm4.10010. (PMID: 10.1002/jbm4.10010)
Naidu A, Malmquist MP, Denham CA, Schow SR (2014) Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg 72(12):2469–2484. https://doi.org/10.1016/j.joms.2014.06.456. (PMID: 10.1016/j.joms.2014.06.45625262402)
Pogrel MA, Hossaini-Zadeh M (2021) Denosumab for the management of central giant cell granuloma of the jaws-a case series. Int J Oral Maxillofac Surg 50(8):1019–1022. https://doi.org/10.1016/j.ijom.2020.12.013. (PMID: 10.1016/j.ijom.2020.12.01333468436)
Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675. https://doi.org/10.1038/nmeth.2089. (PMID: 10.1038/nmeth.208955545425554542)
Bredell M, Rordorf T, Kroiss S, Rucker M, Zweifel DF, Rostetter C (2018) Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study. J Oral Maxillofac Surg 76(4):775–784. https://doi.org/10.1016/j.joms.2017.09.013. (PMID: 10.1016/j.joms.2017.09.01329035698)
Schreuder WH, Coumou AW, Kessler PA, de Lange J (2014) Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab. J Oral Maxillofac Surg 72(7):1301–1309. https://doi.org/10.1016/j.joms.2014.02.017. (PMID: 10.1016/j.joms.2014.02.01724835517)
da Silva NG, Carreira AS, Pedreira EN, Tuji FM, Ortega KL, de Jesus Viana Pinheiro J (2012) Treatment of central giant cell lesions using bisphosphonates with intralesional corticosteroid injections. Head Face Med 8:23. https://doi.org/10.1186/1746-160X-8-23. (PMID: 10.1186/1746-160X-8-2322913518)
Landesberg R, Eisig S, Fennoy I, Siris E (2009) Alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg 67(5 Suppl):27–34. https://doi.org/10.1016/j.joms.2008.12.006. (PMID: 10.1016/j.joms.2008.12.00619371812)
Gossai N, Hilgers MV, Polgreen LE, Greengard EG (2015) Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumour of bone. Pediatr Blood Cancer 62(6):1078–1080. https://doi.org/10.1002/pbc.25393. (PMID: 10.1002/pbc.2539325556556)
Marpuri I, Cheung CC, Moke DJ, Ryabets-Lienhard A (2021) Symptomatic rebound hypercalcemia after denosumab discontinuation in a pediatric patient with cherubism. J Endocr Soc. 5(S1):A706-707. https://doi.org/10.1210/jendso/bvab048.1439. (PMID: 10.1210/jendso/bvab048.14398089891)
Huang B, Law MW, Khong PL (2009) Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 251(1):166–174. https://doi.org/10.1148/radiol.2511081300. (PMID: 10.1148/radiol.251108130019251940)
Ludlow JB, Davies-Ludlow LE, White SC (2008) Patient risk related to common dental radiographic examinations: the impact of 2007 international commission on radiological protection recommendations regarding dose calculation. J Am Dent Assoc 139(9):1237–1243. https://doi.org/10.14219/jada.archive.2008.0339. (PMID: 10.14219/jada.archive.2008.033918762634)
Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT, Kransdorf MJ (2001) Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics 21(5):1283–1309. https://doi.org/10.1148/radiographics.21.5.g01se251283. (PMID: 10.1148/radiographics.21.5.g01se25128311553835)
Edwards PC (2015) Insight into the pathogenesis and nature of central giant cell lesions of the jaws. Med Oral Patol Oral Cir Bucal 20(2):e196-198. https://doi.org/10.4317/medoral.20499. (PMID: 10.4317/medoral.20499256813714393982)
Gomes CC, Gayden T, Bajic A, Harraz OF, Pratt J, Nikbakht H, Bareke E et al (2018) TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. Nat Commun 9(1):4572. https://doi.org/10.1038/s41467-018-06690-4. (PMID: 10.1038/s41467-018-06690-4303857476212533)
Contributed Indexing:: Keywords: Central giant cell granuloma; Denosumab; Hypercalcemia; Hypocalcemia; Jaw neoplasms; Osteonecrosis of the jaw
Substance Nomenclature:: 0 (Bone Density Conservation Agents)
4EQZ6YO2HI (Denosumab)
Entry Date(s):: Date Created: 20220128 Date Completed: 20220425 Latest Revision: 20220425
Update Code:: 20240105
DOI:: 10.1007/s00223-021-00935-z
PMID:: 35088118
: Czasopismo naukowe

Full Text Finder

Central giant cell granuloma (CGCG) is a rare lesion of the jaw occurring in young adults and adolescents. Surgery, the traditional mainstay of therapy, is associated with significant morbidity. Denosumab, a humanised monoclonal antibody to RANKL, is effective in a related entity, giant cell tumour of bone (GCTB), but experience in the more indolent CGCG is limited. This prospective observational study of all denosumab-treated CGCG at a tertiary referral centre (2015-2021) aimed to evaluate the safety, efficacy and recurrence risk using denosumab in CGCG at lower-frequency dosing than used for GCTB. All received standardised, time-limited courses of denosumab 120 mg with stepwise increase in dosing interval based on response. They were followed for up to 75 months using a radiation-minimising protocol: 3-monthly clinical, biochemical and radiological assessment (orthopantomograms, cone beam CT). Eight patients, median age 20.5 years [IQR 6], received 13 initial doses [IQR 10] of denosumab 120 mg. Radiologic response was seen after 5.5 doses [IQR 4.5]: ossification in all and size reduction in three. Recurrence occurred in four of seven completing therapy, observed 12 months post-cessation [IQR 6.5]. Larger baseline size, aggressive subtype and fewer than 12 initial doses were more common in the recurrence group. There was no osteonecrosis of the jaw. Hypocalcaemia occurred in one receiving modified dosing. This study represents the largest, most diverse cohort of denosumab-treated CGCG with the longest follow-up in literature. It demonstrates the efficacy of lower-frequency, time-restricted course of denosumab but highlights the risk of recurrence. Long-term follow-up is critical.
(© 2021. Crown.)

Informacja